Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset
Yuichiro Ohe(National Cancer Center), Kazuhiko Nakagawa(Osaka Red Cross Hospital), Fumio Imamura(Osaka International Cancer Institute), Rachel Hodge(GlaxoSmithKline (United Kingdom)), Takayasu Kurata(Kansai Medical University), Isamu Okamoto(Kyushu University Hospital), Sarah L. Vowler(University of Cambridge), Andrew Walding(AstraZeneca (United Kingdom)), Suresh S. Ramalingam(Emory University), Hirohiko Uchida(AstraZeneca (Japan)), Terufumi Kato(Taipei Veterans General Hospital), Shunichi Sugawara(Sendai Kousei Hospital), Naoyuki Nogami(Hospital Universitario Insular de Gran Canaria)
Cited by 153
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k